Centaurus Financial Inc. Boosts Stake in Danaher Corporation $DHR

Centaurus Financial Inc. lifted its position in Danaher Corporation (NYSE:DHR) by 22.2% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 22,094 shares of the conglomerate’s stock after purchasing an additional 4,016 shares during the quarter. Centaurus Financial Inc.’s holdings in Danaher were worth $4,364,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. WFA of San Diego LLC purchased a new position in shares of Danaher during the second quarter worth approximately $26,000. Howard Hughes Medical Institute acquired a new stake in Danaher during the 2nd quarter worth $27,000. Red Tortoise LLC grew its position in Danaher by 175.0% during the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock worth $30,000 after purchasing an additional 98 shares during the last quarter. Ramirez Asset Management Inc. purchased a new position in Danaher during the 2nd quarter worth $40,000. Finally, Twin Peaks Wealth Advisors LLC acquired a new position in Danaher in the second quarter valued at $51,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Down 2.4%

NYSE:DHR opened at $226.70 on Friday. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $258.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The stock has a fifty day moving average price of $218.51 and a two-hundred day moving average price of $205.78. The stock has a market capitalization of $160.13 billion, a price-to-earnings ratio of 46.74, a PEG ratio of 4.39 and a beta of 0.89.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The business had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.71 EPS. As a group, sell-side analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, December 26th. Danaher’s dividend payout ratio (DPR) is presently 26.39%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. TD Cowen increased their target price on shares of Danaher from $250.00 to $260.00 and gave the stock a “buy” rating in a research note on Wednesday, October 22nd. Evercore ISI increased their price objective on Danaher from $226.00 to $245.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. JPMorgan Chase & Co. upped their price target on Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Finally, Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research report on Tuesday, September 2nd. Twenty-one equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $246.79.

Insider Transactions at Danaher

In other Danaher news, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the sale, the senior vice president directly owned 14,553 shares in the company, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the transaction, the senior vice president owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. This represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 30,248 shares of company stock valued at $6,609,663 in the last quarter. 11.10% of the stock is currently owned by corporate insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.